Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study - Concepedia

Concepedia

Publication | Open Access

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

DOI Full Paper Access

22

Citations

14

References

2023

Year

B. Singer, Douglas L. Arnold, Jelena Drulović, Mark S. Freedman, Ralf Gold, Mark Gudesblatt, Elżbieta Jasińska, Christopher LaGanke, Robert T. Naismith, Donald Negroski,

Multiple Sclerosis Journal

Abstract

DRF was generally well tolerated over 2 years, with few discontinuations due to AEs; radiological measures indicated decreased disease activity from baseline. These outcomes support DRF as a treatment option in patients with RRMS.

References

	Year	Citations

Page 1